Martin Fan
Stock Analyst at Wedbush
(2.93)
# 1,632
Out of 4,981 analysts
7
Total ratings
71.43%
Success rate
32.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Outperform | $40 → $45 | $23.20 | +93.97% | 2 | Aug 7, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $9.90 | +283.84% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $1.97 | +306.09% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $16.15 | +147.68% | 1 | May 15, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Outperform | $18 | $2.66 | +576.69% | 1 | Mar 25, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $35 | $20.17 | +73.53% | 1 | Mar 20, 2025 |
AnaptysBio
Aug 7, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $23.20
Upside: +93.97%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $9.90
Upside: +283.84%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $1.97
Upside: +306.09%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $16.15
Upside: +147.68%
Artiva Biotherapeutics
Mar 25, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.66
Upside: +576.69%
Zenas BioPharma
Mar 20, 2025
Initiates: Outperform
Price Target: $35
Current: $20.17
Upside: +73.53%